“Drug‐Carrier” Synergy Therapy for Amyloid‐β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly
Open Access
- 20 March 2022
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 9 (14) , e2106072
Abstract
Amyloid‐β (Aβ) toxicity is considered to be companioned by Tau phosphorylation in Alzheimer's disease (AD). The clinical AD therapy is usually subjected to low blood‐brain barrier (BBB) penetration and complex interaction mechanisms between Aβ and phosphorylated Tau. A “Drug‐Carrier” synergy therapy is herein designed to simultaneously target Aβ and Tau‐associated pathways for AD treatment. To imitate natural nanoparticle configuration, the endogenous apolipoprotein A‐I and its mimicking peptide 4F fused angiopep‐2 (Ang) are sequentially grafted onto lipid nanocomposite (APLN), providing liberty of BBB crossing and microglia targeted Aβ clearance. For synergy treatment, methylene blue (MB) is further assembled into APLN (APLN/MB) for Tau aggregation inhibition. After intravenous administration, the optimized density (5 wt%) of Ang ligands dramatically enhances APLN/MB intracerebral shuttling and accumulation, which is 2.15‐fold higher than that Ang absent‐modification. The site‐specific release of MB collaborates APLN to promote Aβ capture for microglia endocytosis clearance and reduce p‐Tau level by 25.31% in AD pathogenesis. In AD‐Aβ–Tau bearing mouse models, APLN/MB can relieve AD symptoms, rescue neuron viability and cognitive functions. Collectively, it is confirmed that “Drug‐Carrier” synergy therapy of APLN/MB is a promising approach in the development of AD treatments.Keywords
Funding Information
- National Natural Science Foundation of China (82073401, 82104097, 81872819, 82073795)
- Natural Science Foundation of Jiangsu Province (BK20210426)
- China Postdoctoral Science Foundation (2020TQ0359, 2020M681790)
- Guizhou Medical University ([2022] 387)
This publication has 55 references indexed in Scilit:
- GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer’s DiseaseACS Nano, 2015
- Microglial Aβ Receptors in Alzheimer’s DiseaseCellular and Molecular Neurobiology, 2014
- The glia/neuron ratio: How it varies uniformly across brain structures and species and what that means for brain physiology and evolutionGlia, 2014
- Amyloid-β and TauJAMA Neurology, 2014
- Animal models of Alzheimer's disease and drug developmentDrug Discovery Today: Technologies, 2013
- Hybrid Melittin Cytolytic Peptide-Driven Ultrasmall Lipid Nanoparticles Block Melanoma Growth in VivoACS Nano, 2013
- Association of Higher Levels of High-Density Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer DiseaseArchives of Neurology, 2010
- Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse ModelsCell, 2010
- Human apolipoprotein A–I binds amyloid-β and prevents Aβ-induced neurotoxicityThe International Journal of Biochemistry & Cell Biology, 2009
- Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrilsNature, 1996